Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

A. Cortellini, A. Friedlaender, G.L. Banna, G. Porzio, M. Bersanelli, F. Cappuzzo, J.G.J.V. Aerts, R. Giusti, E. Bria, D. Cortinovis, F. Grossi, M.R. Migliorino, D. Galetta, F. Passiglia, R. Berardi, F. Mazzoni, V. Di Noia, D. Signorelli, A. Tuzi, A. GelibterP. Marchetti, M. Macerelli, F. Rastelli, R. Chiari, D. Rocco, A. Inno, P. Di Marino, G. Mansueto, F. Zoratto, M. Santoni, M. Tudini, M. Ghidini, M. Filetti, A. Catino, P. Pizzutilo, L. Sala, M.A. Occhipinti, F. Citarella, R. Marco, M. Torniai, L. Cantini, A. Follador, V. Sforza, O. Nigro, M.G. Ferrara, E. D'Argento, A. Leonetti, L. Pettoruti, L. Antonuzzo, S. Scodes, L. Landi, G. Guaitoli, C. Baldessari, F. Bertolini, L. Della Gravara, M.G. Dal Bello, R.A. Belderbos, M. De Filippis, C. Cecchi, S. Ricciardi, C. Donisi, A. De Toma, C. Proto, A. Addeo, O. Cantale, B. Ricciuti, C. Genova, A. Morabito, D. Santini, C. Ficorella, K. Cannita

Research output: Contribution to journalArticlepeer-review

Abstract

The role of immune-related adverse event (irAE) occurrence, as a surrogate predictor of the clinical efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer with a programmed death-ligand 1 expression of ≥ 50%. A total of 1010 patients were evaluated, and after a 6-week landmark selection, 877 patients were included. We confirmed the irAE profile of first-line, single-agent pembrolizumab, in a large, real-life cohort of patients with non–small-cell lung-cancer with programmed death-ligand 1 expression of ≥ 50%. The occurrence of irAEs might be considered a surrogate of clinical activity and improved outcomes also in this setting. © 2020 Elsevier Inc. Background: The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non–small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%. Patients and Methods: We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes. Results: A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P
Original languageEnglish
JournalClin. Lung Cancer
DOIs
Publication statusPublished - 2020

Keywords

  • ONCOLOGIA
  • STUDIO CLINICO
  • RIS

Fingerprint

Dive into the research topics of 'Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes'. Together they form a unique fingerprint.

Cite this